Anti-IL-4/IL-13 for the treatment of asthma: the story so far

Journal article

Introduction: Severe asthma is a global health concern with high morbidity and mortality. Understanding of its complex pathophysiology continues to increase, providing specific immune targets for therapeutic intervention.

Areas covered: In this review, we focus on the role of IL-4 and IL-13 in severe asthma and on the biologic therapies developed to target them, particularly dupilumab, a monoclonal antibody against the IL-4 receptor α subunit and IL-4/IL-13 receptor complex. A literature search was undertaken for all studies of monoclonal antibodies against IL-4 and IL-13.

Expert Opinion: Dupilumab decreases the rate of severe asthma exacerbations and improves symptoms, lung function, and quality of life. Importantly, these effects are also observed during reduction of maintenance oral corticosteroid doses. Those with the highest T2 biomarkers derive the greatest benefit and the presence of atopic dermatitis or chronic rhinosinusitis with or without nasal polyposis may recommend dupilumab as the preferred biologic treatment for a patient.

Authors: Moran, A; Pavord, ID

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Taylor & Francis
• Journal: Expert Opinion on Biological Therapy
• Volume: 20
• Issue: 3
• Pages: 283-294
• Publication date: 2020-01-20
• Acceptance date: 2020-01-07
• DOI: 10.1080/14712598.2020.1714027
• EISSN: 1744-7682
• ISSN: 1471-2598
• Pmid: 31914819
• Language: English
• Keywords: T2 asthma; FFR; IL-4; dupilumab; IL-13; biologics